Gene-expression signatures in oncology diagnostics.
The advent of DNA microarray technologies has enabled the development of gene expression signatures that can be used for prognostic and predictive purposes. This new information can change the paradigm of how medicine is practiced, coupling physical examination, pathology and clinical tests with new molecular information. However, many unanswered questions regarding sample acquisition, platform development, signature validation and clinical trial design will need to be addressed before this new medical content will have an impact on the clinical setting. This article will examine some of these issues in greater detail, focusing on tissue type, platform comparison, biospecimen collection and signature validation.
Mazumder
Abhijit
A
Veridex LLC, a Johnson & Johnson Company, 3210 Merryfield Row, San Diego, CA 92121, USA.
Wang
Yixin
Y
D020869:Gene Expression Profiling / Q000379:methods*; D006801:Humans; D009369:Neoplasms / Q000175:diagnosis* / Q000235:genetics*; D020411:Oligonucleotide Array Sequence Analysis; D011379:Prognosis; D012313:RNA / Q000235:genetics; D013048:Specimen Handling
D012313:RNA